NASDAQ:SNGX

Soligenix Stock News

Healthcare > Biotechnology

Buy SNGX

*Your capital is at risk

$1.35

-0.0200 (-1.46%)

At Close: Nov 17, 2025

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

07:30am, Friday, 07'th Nov 2025

PRINCETON, N.J. , Nov. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

07:30am, Tuesday, 14'th Oct 2025

Providing Strategic Medical Guidance in Advancing HyBryte™ Clinical Development PRINCETON, N.J. , Oct. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stag

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

07:30am, Tuesday, 07'th Oct 2025

FLASH 2 Study Interim Efficacy Analysis Targeted for 1H2026 Enrollment Update Remains on Track for 4Q2025 PRINCETON, N.J. , Oct. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or th

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

07:30am, Tuesday, 30'th Sep 2025

In preparation for health authority interactions in pursuit of marketing approvals in Europe PRINCETON, N.J. , Sept. 30, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Comp

Soligenix Announces Closing of $7.5 Million Public Offering

04:05pm, Monday, 29'th Sep 2025

Cash runway extended through 2026 to fund multiple expected key inflection points PRINCETON, N.J. , Sept. 29, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a l

Soligenix Announces Pricing of $7.5 Million Public Offering

06:33am, Friday, 26'th Sep 2025

PRINCETON, N.J. , Sept. 26, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing product

Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

07:30am, Tuesday, 23'rd Sep 2025

Contributing Broad Business and Government Affairs Expertise and Network PRINCETON, N.J. , Sept. 23, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopha

Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses

07:30am, Thursday, 04'th Sep 2025

Two Year Stability demonstrated in both bivalent and trivalent configurations at temperatures of 40°C / 104°F PRINCETON, N.J. , Sept. 4, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligeni

Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference

07:30am, Tuesday, 02'nd Sep 2025

PRINCETON, N.J. , Sept. 2, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to

Why Is Soligenix Stock Soaring On Monday?

01:03pm, Monday, 18'th Aug 2025

Soligenix, Inc. SNGX stock is higher on Monday after the U.S. Food and Drug Administration granted orphan drug designation to dusquetide, the active ingredient in SGX945, for Behçet's Disease.

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

07:30am, Monday, 18'th Aug 2025

Provides SGX945 Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage bioph

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by